News

FDA approves alirocumab, first injectable lipid-lowering biologic therapy

Publish date: July 24, 2015

 

FROM THE FDA

References

The prescribing information is available at http://1.usa.gov/1KpIU82.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

Biologics cut cholesterol, may reduce mortality
MDedge Endocrinology
AUA: Testosterone may not deserve its reputation as a cardiovascular culprit
MDedge Endocrinology
FDA panel set to review two biologic lipid-lowering drugs for approval
MDedge Endocrinology
Panel backs approval of alirocumab, biologic injectable lipid-lowering drug
MDedge Endocrinology
FDA panel backs evolocumab for lowering LDL in high-risk patients
MDedge Endocrinology
ADA: DPP4 inhibitors and cardiovascular outcomes: connecting the dots
MDedge Endocrinology
Half of Hispanics unaware of their high cholesterol
MDedge Endocrinology
Study quantifies risks linked to cardiac multimorbidity
MDedge Endocrinology
FDA will strengthen heart attack, stroke risk warnings for all NSAIDs
MDedge Endocrinology
ACC/AHA cholesterol guideline found efficient, cost effective
MDedge Endocrinology

Related Articles